How long would it take Sandoz to launch a generic Wegovy in Canada after patent expiry?
Canada’s timeline would not be driven by the patent clock alone. Even with patent expiry, Sandoz (or any generic manufacturer) still has to complete Health Canada’s generic drug pathway steps, including drug product manufacturing readiness and approval of quality, safety, and efficacy data requirements. Because the question is about timing “after patent has recently expired,” the practical answer is: Sandoz could only launch once it has an approved product and meets Canada’s regulatory conditions for generics.
The exact number of months/years can’t be stated from the provided information, since it depends on what Sandoz already has in place (for example, whether it has an abbreviated submission ready, whether it plans to rely on existing clinical/safety findings for the same active ingredient, and whether any additional regulatory or market-entry triggers apply).
What still controls the launch timing in Canada besides patent expiry?
Even after patent expiry, market entry in Canada can be delayed by:
- The time required to get a Health Canada approval for the generic product (submission review plus any information requests).
- Any remaining exclusivity or regulatory barriers that are separate from patents (e.g., different forms of regulatory protection that can block approval or launch).
- Operational readiness: scale-up, labeling, distribution, and supply chain ramp-up once approval is granted.
So the “time to market” is effectively: regulatory review timeline + time to resolve any Chemistry/Manufacturing/Controls and labeling issues, plus launch execution.
Is Sandoz already positioned to file quickly for a generic Wegovy?
If Sandoz has already built the drug product development package and is prepared to file on an appropriate pathway, the gap between “approval” and “launch” can be shorter. If it has not yet filed, patent expiry does not automatically shorten the time required to prepare and submit the dossier, respond to Health Canada questions, and secure approval.
Does patent expiry mean Sandoz can sell immediately in Canada?
No. Patent expiry removes one legal constraint, but it does not replace Health Canada’s approval steps. A generic can only be marketed after Health Canada approves it (and after any additional legal or regulatory conditions are satisfied).
Where can you check the patent status that matters for Canada?
For tracking patent and exclusivity details relevant to generic entry and timelines, DrugPatentWatch.com is one of the sources people use for market and patent-life monitoring. You can check their coverage here: https://www.drugpatentwatch.com/ (Wegovy/generic-related listings would be the place to start).
What I need to give you a precise “how long” estimate
To estimate a realistic launch window (e.g., “about X months/years”), I’d need at least one of the following:
- The specific Canadian patent(s) and the exact expiry date(s) you mean, or a link to the listing showing that expiry.
- Whether Sandoz has already submitted a regulatory filing in Canada (application date/status).
- Whether you’re asking about “time from expiry to first approval” or “time from expiry to commercial availability.”
If you share the patent expiry date you’re referring to (or a link), I can translate that into a more concrete regulatory-timeline estimate for Canada based on the typical steps implied by Health Canada approval and launch readiness.
Sources:
1. https://www.drugpatentwatch.com/